Clinical Pipeline

Phase 1Phase 2Phase 3


Oral LSD1 inhibitor (Hematological Malignancies)


Ownership: Taiho

Mechanism of Action: Lysine-Specific Histone Demethylase 1 (LSD1) inhibition

Indication: Relapsed/refractory Acute Myeloid Leukemia (AML)

How this therapy can help

TAS1440 is a Lysine-Specific Histone Demethylase 1 inhibitor (LSD1 [also named KDM1A]). LSD1 is an epigenetic regulator. It is aberrantly expressed in many cancers, including AML, where it impedes cellular differentiation which may contribute to leukemia development, cancer cell proliferation, cell metastasis, and invasiveness, and is associated with inferior prognosis.

Clinical status

TAS1440 is being evaluated in a first-in-human Phase 1 clinical study in patients with relapsed/refractory AML.

View clinical studies and status

View Presentations and Publications